Gene therapy company UniQure had another FDA meeting after Vinay Prasad's exit.
UniQure, a gene therapy company, experienced a significant turnaround as its previously rejected gene therapy gained renewed consideration from the FDA. This positive development occurred after a new meeting, following the exit of a key official. The change in stance signals…
Market Samachar is a news aggregator. This article was originally published by Ars Technica. Tap the button above to read the full story on their site.